Toleranzia
0.598 SEK +0.34%Be the first to follow this company
Toleranzia is a research company focused on the development of drug candidates for the treatment of autoimmune diseases. The company has developed a platform technology focused on the muscular disease myasthenia gravis. In addition, the technology has been used in other areas such as diabetes and multiple sclerosis. Research collaboration is done together with external partners within the field. The head office is based in Gothenburg.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
TOL
Daily low / high price
0.576 / 0.6
SEK
Market cap
117.85M SEK
Turnover
56.49K SEK
Volume
95K
Financial calendar
Interim report
23.08.2024
Interim report
24.10.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Flerie Invest AB | 57.1 % | 57.1 % |
Avanza Pension | 3.4 % | 3.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Announcement from the 2024 Annual General Meeting of Toleranzia AB (publ)
Toleranzia AB conducts successful safety study of TOL2 in blood samples from patients with myasthenia gravis
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools